Comparative assessment of clinical benefit using the ESMO Magnitude of Clinical Benefit Scale version 1.1 and the ASCO Value Framework Net Health Benefit Score

19 December 2018 - To better understand the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) ...

Read more →

The use of MCDA in HTA: great potential, but more effort needed

18 April 2018 - The potential for multi-criteria decision analysis (MCDA) to support health technology assessment (HTA) has been much discussed, ...

Read more →

Decision components of NICE's technology appraisals assessment framework

10 April 2018 - The UK's NICE is an established health technology assessment agency. de Folter et al. present a ...

Read more →

A health economics approach to US value frameworks: serving the needs of decision-making

22 February 2018 - Value assessment is an integral component of decision making in health and is the focus of a ...

Read more →

Patient-centered decision making: lessons from multi-criteria decision analysis for quantifying patient preferences

26 December 2018 - Patient preferences should be a central consideration in healthcare decision making.  ...

Read more →

Statement from FDA Commissioner on FDA’s comprehensive new policy approach to facilitating the development of innovative regenerative medicine products to improve human health

16 November 2017 - One of the most promising fields of science is the area of cell-based therapies and their ...

Read more →

Institute for Clinical and Economic Review announces final modified framework for assessing value of treatments for ultra rare diseases

13 November 2017 - Broader societal considerations and expanded cost-effectiveness ranges will be included for treatments targeting fewer than 10,000 patients. ...

Read more →

Social value and individual choice: the value of a choice-based decision-making process in a collectively funded health system

4 October 2017 - Evidence about cost-effectiveness is increasingly being used to inform decisions about the funding of new technologies that ...

Read more →

Time for a change in how new antibiotics are reimbursed: development of an insurance framework for funding new antibiotics based on a policy of risk mitigation

9 October 2017 - Healthcare systems depend on the availability of new antibiotics.  ...

Read more →

New advance value framework offered as a decision-support tool for reimbursement

25 September 2017 - Researchers at the London School of Economics and Political Science have developed a multiple criteria decision ...

Read more →

Should value frameworks take a ‘societal perspective’?

6 September 2017 - In 1996, the U.S. Panel on Cost-Effectiveness in Health and Medicine recommended that analysts conducting cost-effectiveness ...

Read more →

Can a new value framework help ease friction over orphan drug prices?

7 September 2017 - America’s healthcare debate has stalled in Congress, but constructive dialogue and innovation are thriving in specialised ...

Read more →

FDA’s plan to engage the public in the agency’s new effort to strengthen and modernise FDA’s regulatory framework

7 September 2017 - We’re at a moment of extraordinary opportunity to improve the public health. New innovations are giving us ...

Read more →

How to design the cost-effectiveness appraisal process of new health care technologies to maximise population health: a conceptual framework

22 August 2017 - This paper presents a conceptual framework to analyse the design of the cost-effectiveness appraisal process of new ...

Read more →

Using discrete choice experiments to inform the benefit-risk assessment of medicines: are we ready yet?

23 August 2017 - There is emerging interest in the use of discrete choice experiments as a means of quantifying the ...

Read more →